dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Nicotinic acetylcholine receptors  (nACh) (type: lgic)
Target: nicotinic acetylcholine receptor &alpha;2 subunit

Ligand: [3H]epibatidine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 10.380000114440918 pKd

Ligand: [3H]epibatidine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd

Ligand: [3H]epibatidine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd

Ligand: [3H]cytisine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [125I]epibatidine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd

Ligand: [125I]epibatidine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 10.380000114440918 pKd

Ligand: [125I]epibatidine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd

Ligand: mecamylamine (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (2013)
Primary target: no
Median affinity:  -

Ligand: LY2087101 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators.
Published in: J Pharmacol Exp Ther

Ligand: hexamethonium (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: CP-601927 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: yes
Median affinity: 8.920000076293945 pKi
Reference (Journal): α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties.
Published in: Behav Pharmacol
Target family: Nicotinic acetylcholine receptors  (nACh) (type: lgic)
Target: nicotinic acetylcholine receptor &alpha;1 subunit

Ligand: waglerin-1 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [3H]α-bungarotoxin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [125I]α-bungarotoxin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: succinylcholine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1952)
Primary target: yes
Median affinity:  -

Ligand: pancuronium (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1990)
Primary target: yes
Median affinity:  -

Ligand: mecamylamine (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (2013)
Primary target: no
Median affinity: 5.820000171661377 pIC50

Ligand: gallamine (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Primary target: no
Median affinity: 6 pIC50

Ligand: atracurium (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1983), UK (1999)
Primary target: no
Median affinity: 7.010000228881836 pIC50
Reference (Journal): Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade.
Published in: Anesthesiology
Target family: Nicotinic acetylcholine receptors  (nACh) (type: lgic)
Target: nicotinic acetylcholine receptor &alpha;9 subunit

Ligand: [3H]α-bungarotoxin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [125I]α-bungarotoxin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: strychnine (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: strychnine (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: RgIA4 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 8.819999694824219 pIC50
Reference (Journal): Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain.
Published in: Proc Natl Acad Sci USA

Ligand: RgIA4 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.050000190734863 pIC50
Reference (Journal): Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain.
Published in: Proc Natl Acad Sci USA

Ligand: nicotine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: no
Median affinity:  -

Ligand: nicotine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: no
Median affinity:  -

Ligand: muscarine (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: muscarine (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-conotoxin RgIA (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-bungarotoxin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-bungarotoxin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Nicotinic acetylcholine receptors  (nACh) (type: lgic)
Target: nicotinic acetylcholine receptor &alpha;8 subunit (avian)

Ligand: [3H]epibatidine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity: 9.7 pKd

Ligand: [3H]α-bungarotoxin (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity: 8.26 pKd

Ligand: [125I]α-bungarotoxin (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity: 8.26 pKd
Target family: Nicotinic acetylcholine receptors  (nACh) (type: lgic)
Target: nicotinic acetylcholine receptor &alpha;7 subunit

Ligand: [3H]methyllycaconitine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.720000267028809 pKd

Ligand: PSAB-OFP (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pEC50
Reference (Journal): PSAB-OFP, a selective alpha 7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor.
Published in: Eur J Pharmacol

Ligand: [3H]epibatidine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 12.220000267028809 pKd
Target family: Nicotinic acetylcholine receptors  (nACh) (type: lgic)
Target: nicotinic acetylcholine receptor &alpha;1 subunit

Ligand: α-conotoxin MI (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-conotoxin GI (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-bungarotoxin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Nicotinic acetylcholine receptors  (nACh) (type: lgic)
Target: nicotinic acetylcholine receptor &alpha;10 subunit

Ligand: [3H]methyllycaconitine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.119999885559082 pKd

Ligand: strychnine (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: RgIA4 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.050000190734863 pIC50
Reference (Journal): Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain.
Published in: Proc Natl Acad Sci USA

Ligand: RgIA4 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.819999694824219 pIC50
Reference (Journal): Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain.
Published in: Proc Natl Acad Sci USA

Ligand: nicotine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: no
Median affinity:  -

Ligand: muscarine (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-conotoxin RgIA (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-bungarotoxin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Nicotinic acetylcholine receptors  (nACh) (type: lgic)
Target: nicotinic acetylcholine receptor &alpha;5 subunit

Ligand: α-conotoxin-GIC (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-conotoxin MII (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-conotoxin PnIA (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-conotoxin TxIA (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Nicotinic acetylcholine receptors  (nACh) (type: lgic)
Target: nicotinic acetylcholine receptor &alpha;6 subunit

Ligand: α-conotoxin MII (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-conotoxin MII [H9A, L15A] (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-conotoxin PIA (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: hexamethonium (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 4.039999961853027 pIC50

Ligand: mecamylamine (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (2013)
Primary target: no
Median affinity: 4.960000038146973 pIC50

Ligand: [125I]α-conotoxin MII (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [3H]epibatidine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 10.460000038146973 pKd
Target family: Nicotinic acetylcholine receptors  (nACh) (type: lgic)
Target: nicotinic acetylcholine receptor &alpha;3 subunit

Ligand: α-conotoxin PnIA (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-conotoxin MII (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: α-conotoxin-GIC (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Nicotinic acetylcholine receptors  (nACh) (type: lgic)
Target: nicotinic acetylcholine receptor &delta; subunit

Ligand: PhTX-11 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Solid-phase synthesis and pharmacological evaluation of analogues of PhTX-12-A potent and selective nicotinic acetylcholine receptor antagonist.
Published in: Bioorg Med Chem Lett
Target family: Nicotinic acetylcholine receptors  (nACh) (type: lgic)
Target: nicotinic acetylcholine receptor &alpha;9 subunit

Ligand: [3H]methyllycaconitine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.119999885559082 pKd
Target family: NIM1 subfamily (type: enzyme)
Target: serine/threonine-protein kinase NIM1

Ligand: compound 89S [PMID: 19115845] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.400000095367432 pIC50
Reference (Journal): First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
Published in: J Med Chem
Target family: NIMA (never in mitosis gene a)- related kinase (NEK) family (type: enzyme)
Target: NIMA related kinase 1

Ligand: compound 31 [PMID: 20936789] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.769999980926514 pIC50
Reference (Journal): Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization.
Published in: J Med Chem
Target family: NIMA (never in mitosis gene a)- related kinase (NEK) family (type: enzyme)
Target: NIMA related kinase 11

Ligand: compound 25 [PMID: 17935989] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.809999942779541 pKi
Reference (Journal): Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.
Published in: Bioorg Med Chem Lett
Target family: NIMA (never in mitosis gene a)- related kinase (NEK) family (type: enzyme)
Target: NIMA related kinase 2

Ligand: compound 2 [PMID: 21627121] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.220000267028809 pIC50
Reference (Journal): Irreversible Nek2 kinase inhibitors with cellular activity.
Published in: J Med Chem

Ligand: compound 31 [PMID: 20936789] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.639999866485596 pIC50
Reference (Journal): Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization.
Published in: J Med Chem

Ligand: GSK579289A (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.679999828338623 pIC50
Reference (Journal): Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.
Published in: Bioorg Med Chem Lett
Target family: NIMA (never in mitosis gene a)- related kinase (NEK) family (type: enzyme)
Target: NIMA related kinase 3

Ligand: compound 25 [PMID: 17935989] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.78000020980835 pKi
Reference (Journal): Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.
Published in: Bioorg Med Chem Lett
Target family: NIMA (never in mitosis gene a)- related kinase (NEK) family (type: enzyme)
Target: NIMA related kinase 6

Ligand: compound 22 [PMID: 20462760] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.
Published in: Bioorg Med Chem Lett
Target family: NIMA (never in mitosis gene a)- related kinase (NEK) family (type: enzyme)
Target: NIMA related kinase 7

Ligand: compound 22 [PMID: 20462760] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.
Published in: Bioorg Med Chem Lett

Ligand: ofirnoflast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Patent): Inhibitors of nek7 kinase
Target family: Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase (type: catalytic_receptor)
Target: Guanylyl cyclase, &alpha;<sub>1</sub>&beta;<sub>1</sub>

Ligand: ODQ (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.5 pIC50
Reference (Journal): Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.
Published in: Mol Pharmacol
Target family: Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase (type: catalytic_receptor)
Target: Guanylyl cyclase, &alpha;<sub>2</sub>&beta;<sub>1</sub>

Ligand: YC-1 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Functional properties of a naturally occurring isoform of soluble guanylyl cyclase.
Published in: Biochem J

Ligand: YC-1 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): YC-1, a novel activator of platelet guanylate cyclase.
Published in: Blood

Ligand: vericiguat (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: EMA & FDA (2021)
Primary target: no
Median affinity:  -
Reference (Journal): Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
Published in: J Med Chem

Ligand: riociguat (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (2013), EMA (2014)
Primary target: no
Median affinity:  -
Reference (Journal): NO-independent regulatory site on soluble guanylate cyclase.
Published in: Nature

Ligand: riociguat (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (2013), EMA (2014)
Primary target: no
Median affinity:  -
Reference (Journal): NO-independent, haem-dependent soluble guanylate cyclase stimulators.
Published in: Handb Exp Pharmacol

Ligand: olinciguat (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential.
Published in: Nitric Oxide

Ligand: ODQ (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: cinaciguat (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.
Published in: Br J Pharmacol
Target family: Nitric oxide synthases (type: enzyme)
Target: Neuronal NOS

Ligand: Nωpropyl-L-arginine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.199999809265137 pKi
Reference (Journal): Potent and selective inhibition of neuronal nitric oxide synthase by N omega-propyl-L-arginine.
Published in: J Med Chem

Ligand: L-NNA (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.820000171661377 pKi
Reference (Journal): N-Phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: structure-activity studies and demonstration of in vivo activity.
Published in: J Med Chem

Ligand: GW274150 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.739999771118164 pIC50
Reference (Journal): 2-aminopyridines as highly selective inducible nitric oxide synthase inhibitors. Differential binding modes dependent on nitrogen substitution.
Published in: J Med Chem

Ligand: compound 14j [PMID: 27050842] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.889999866485596 pKi
Reference (Journal): Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker.
Published in: J Med Chem

Ligand: compound 14j [PMID: 27050842] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pKi
Reference (Journal): Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker.
Published in: J Med Chem

Ligand: 7NI (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 5.3 pIC50
Reference (Journal): Inhibition of rat cerebellar nitric oxide synthase by 7-nitro indazole and related substituted indazoles.
Published in: Br J Pharmacol

Ligand: 3-bromo-7NI (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): 7-Nitro indazole derivatives are potent inhibitors of brain, endothelium and inducible isoforms of nitric oxide synthase.
Published in: Life Sci